Dr. Hartley-Brown's clinical area of focus is treating patients with Multiple
Myeloma. This is an incurable blood cancer, that affects African Americans more
prevalently than other ethnic populations. She also practices clinical research, mainly in the relapsed refractory myeloma disease setting. Dr. Hartley-Brown actively participates as a principal investigator in clinical trials within the Alliance for Clinical Trials, investigator-initiated and investigator sponsored trials. Her area of interest in clinical trials includes use of immunotherapies and targeted therapies, such as
bispecific/tri-specific antibodies, antibody-drug conjugates and modern immune
modulating drugs (ex. cereblon modulators).